ATE320257T1 - (s,s)-reboxetine zur behandlung chronischer schmerzen - Google Patents

(s,s)-reboxetine zur behandlung chronischer schmerzen

Info

Publication number
ATE320257T1
ATE320257T1 AT00941659T AT00941659T ATE320257T1 AT E320257 T1 ATE320257 T1 AT E320257T1 AT 00941659 T AT00941659 T AT 00941659T AT 00941659 T AT00941659 T AT 00941659T AT E320257 T1 ATE320257 T1 AT E320257T1
Authority
AT
Austria
Prior art keywords
reboxetine
treatment
chronic pain
pain
chronic
Prior art date
Application number
AT00941659T
Other languages
English (en)
Inventor
Erik H F Wong
Saeeduddin Ahmed
Robert Clyde Marshall
Robert Mcarthur
Duncan P Taylor
Lars Birgerson
Pasquale Cetera
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE320257(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of ATE320257T1 publication Critical patent/ATE320257T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00941659T 1999-07-01 2000-06-22 (s,s)-reboxetine zur behandlung chronischer schmerzen ATE320257T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US14413199P 1999-07-16 1999-07-16
US15825699P 1999-10-06 1999-10-06
US17038199P 1999-12-13 1999-12-13

Publications (1)

Publication Number Publication Date
ATE320257T1 true ATE320257T1 (de) 2006-04-15

Family

ID=27495506

Family Applications (9)

Application Number Title Priority Date Filing Date
AT04013381T ATE305788T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von inkontinenz
AT04013383T ATE304358T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von migränekopfschmerzen
AT04023888T ATE305306T1 (de) 1999-07-01 2000-06-22 Reboxetin zur behandlung von peripheren neuropathien
AT04025514T ATE305307T1 (de) 1999-07-01 2000-06-22 Reboxetin zur behandlung von migränekopfschmerzen
AT05111704T ATE364386T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
AT00941659T ATE320257T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetine zur behandlung chronischer schmerzen
AT04013379T ATE292971T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von peripheren neuropathien
AT04025513T ATE319453T1 (de) 1999-07-01 2000-06-22 Reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
AT04013382T ATE296634T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen

Family Applications Before (5)

Application Number Title Priority Date Filing Date
AT04013381T ATE305788T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von inkontinenz
AT04013383T ATE304358T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von migränekopfschmerzen
AT04023888T ATE305306T1 (de) 1999-07-01 2000-06-22 Reboxetin zur behandlung von peripheren neuropathien
AT04025514T ATE305307T1 (de) 1999-07-01 2000-06-22 Reboxetin zur behandlung von migränekopfschmerzen
AT05111704T ATE364386T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom

Family Applications After (3)

Application Number Title Priority Date Filing Date
AT04013379T ATE292971T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von peripheren neuropathien
AT04025513T ATE319453T1 (de) 1999-07-01 2000-06-22 Reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
AT04013382T ATE296634T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen

Country Status (31)

Country Link
US (18) US6465458B1 (de)
EP (3) EP2087892A3 (de)
JP (3) JP2003503450A (de)
KR (5) KR100704319B1 (de)
CN (5) CN1205935C (de)
AR (1) AR035158A1 (de)
AT (9) ATE305788T1 (de)
AU (2) AU771258B2 (de)
BR (1) BR0012136A (de)
CA (2) CA2643231A1 (de)
CL (3) CL2008002868A1 (de)
CO (1) CO5190662A1 (de)
CZ (1) CZ299847B6 (de)
DE (9) DE60035232T2 (de)
DK (4) DK1459749T3 (de)
EA (6) EA200801805A1 (de)
ES (9) ES2246488T3 (de)
GE (1) GEP20094798B (de)
HK (2) HK1049630A1 (de)
HU (1) HUP0201623A3 (de)
IL (3) IL147246A0 (de)
MX (1) MXPA02000562A (de)
MY (1) MY137348A (de)
NO (4) NO20016406L (de)
NZ (2) NZ515885A (de)
PE (1) PE20010684A1 (de)
PL (1) PL196996B1 (de)
PT (5) PT1196172E (de)
SK (5) SK286104B6 (de)
TW (9) TWI298255B (de)
WO (1) WO2001001973A2 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286104B6 (sk) * 1999-07-01 2008-03-05 Pharmacia & Upjohn Company Použitie (S,S) reboxetínu na prípravu lieku na liečenie alebo prevenciu chronickej bolesti
WO2001039779A1 (en) * 1999-12-01 2001-06-07 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
KR20020089510A (ko) * 2000-04-21 2002-11-29 파마시아 앤드 업존 캄파니 섬유 근육통 증후군 및 만성 피로 증후군의 치료
NZ531171A (en) 2000-04-21 2005-03-24 Upjohn Co Cabergoline-type compounds for treating fibromyalgia and chronic fatigue syndrome
US20040048860A1 (en) * 2000-10-31 2004-03-11 Jes Olesen Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
WO2002040006A2 (en) * 2000-11-15 2002-05-23 Eli Lilly And Company Treatment of anxiety disorders
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
WO2002102297A2 (en) * 2001-06-19 2002-12-27 Mueller Norbert Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
AU2002347984A1 (en) * 2001-11-30 2003-06-17 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
US20050009925A1 (en) * 2001-12-11 2005-01-13 Bymaster Franklin Porter Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
US20050096395A1 (en) * 2002-02-12 2005-05-05 Rao Srinivas G. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20030232805A1 (en) * 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
MXPA04011203A (es) 2002-05-17 2005-07-14 Univ Duke Metodo para tratar la obesidad.
CN1655787A (zh) * 2002-05-30 2005-08-17 神经研究公司 治疗慢性疼痛的三单胺再摄取抑制剂
ATE439354T1 (de) * 2002-06-17 2009-08-15 Pfizer Italia Srl Pharmazeutische salze von reboxetin
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
NZ537521A (en) * 2002-08-14 2007-05-31 Pharmacia & Upjohn Co Llc Use of reboxetine for the treatment of hot flashes
ES2315525T3 (es) 2002-08-23 2009-04-01 Eli Lilly And Company Derivados de 2-(feniltiometil)-morfolina para uso como inhibidores selectivos de la recaptacion de norepinefrina.
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
DE60305717T2 (de) 2002-08-23 2007-05-03 Eli Lilly And Co., Indianapolis Benzylmorpholinderivate
AU2003284005B2 (en) * 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
WO2004062624A2 (en) * 2003-01-13 2004-07-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
CN100353946C (zh) * 2003-01-13 2007-12-12 戴诺吉药品有限公司 治疗功能性肠病的方法
EP1539181B1 (de) * 2003-04-04 2007-06-27 Dynogen Pharmaceuticals Inc. Methode zur behandlung von erkrankungen der unteren harnwege
DK2316456T3 (en) 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
CA2536161A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
CA2537402C (en) * 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
US20070015786A1 (en) * 2003-12-12 2007-01-18 Eli Lily And Company Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
DE602004019698D1 (de) * 2003-12-23 2009-04-09 Lilly Co Eli Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
AU2005238296A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
CA2567365A1 (en) * 2004-06-09 2006-01-05 Pfizer Inc. Use of reboxetine for the treatment of pain
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
BRPI0513846A (pt) 2004-08-13 2008-05-20 Boehringer Ingelheim Int formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo
US20080261955A1 (en) * 2004-10-01 2008-10-23 Timothy Dinan Use of Pharmaceutical Compositions of Lofepramine for the Treatment of Adhd, Cfs, Fm and Depression
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
ES2402522T3 (es) 2005-11-22 2013-05-06 Orexigen Therapeutics, Inc. Composiciones y procedimientos para aumentar la sensibilidad a la insulina
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2363124B1 (de) * 2006-06-28 2016-02-17 Lundbeck NA Ltd Pharmazeutische Zusammensetzungen enthaltend Droxidopa
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
EP2134335B1 (de) 2007-03-09 2014-04-23 Chelsea Therapeutics, Inc. Droxidopa und pharmazeutische zusammensetzung davon zur behandlung von fibromyalgie
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
CN101720186A (zh) * 2007-04-30 2010-06-02 阿得罗公司 (-)-e-10-oh-nt组合物及其合成与使用的方法
AU2008248382B2 (en) * 2007-05-07 2013-07-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US8940315B2 (en) 2008-04-18 2015-01-27 Medtronic, Inc. Benzodiazepine formulation in a polyorthoester carrier
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
JP5405571B2 (ja) 2008-07-24 2014-02-05 セラヴァンス， インコーポレーテッド ３−（フェノキシフェニルメチル）ピロリジン化合物
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (en) * 2008-10-17 2010-04-22 Pfizer Limited Novel uses for esreboxetine and racemic reboxetine
EP2419405A1 (de) * 2009-04-15 2012-02-22 Theravance, Inc. 3-(phenoxypyrrolidin-3-ylmethyl)heteroaryl-, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl- und 3-(heteroarylpyrrolidin-3-ylmethoxy)heterarylverbindungen
JP5826173B2 (ja) * 2009-07-13 2015-12-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ３−フェノキシメチルピロリジン化合物
WO2011011231A1 (en) 2009-07-21 2011-01-27 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
ES2533434T3 (es) 2010-10-11 2015-04-10 Theravance Biopharma R&D Ip, Llc Inhibidores de la captación de la serotonina
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
WO2016077724A1 (en) 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education (2-amino-4(arylamino)phenyl) carbamates
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
EP3693020A1 (de) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Kaliumangereicherte topische formulierungen zur schmerzlinderung und schlafhilfe
MX2022006630A (es) * 2019-12-03 2022-06-24 Axsome Therapeutics Inc Uso de reboxetina para tratar los trastornos del sistema nervioso.

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
AU642582B2 (en) 1991-02-25 1993-10-21 Eli Lilly And Company Treatment of lower urinary tract disorders
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
CA2250042A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
AU725556B2 (en) 1996-03-25 2000-10-12 Eli Lilly And Company Method for treating pain
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US6572880B2 (en) * 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6479074B2 (en) * 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
DE59600683D1 (de) 1996-11-27 1998-11-19 Pfleger R Chem Fab Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
AU6966998A (en) 1997-04-11 1998-11-11 Eli Lilly And Company Composition for treating pain
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
AU5155198A (en) 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
AU9214498A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
WO1999020279A1 (en) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
ES2244189T3 (es) * 1998-04-09 2005-12-01 PHARMACIA & UPJOHN COMPANY LLC Uso de reboxetina para el tratamiento de trastornos neuropsiquiatricos.
IT1305322B1 (it) 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
CN1300217A (zh) * 1998-05-08 2001-06-20 法玛西雅厄普约翰美国公司 瑞波西汀与吲哚洛尔的新的药物组合
MXPA00012767A (es) 1998-06-29 2002-08-09 Pharmaceuticals Applic Asociat Metodos y composiciones transdermicas para el alivio del dolor.
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
SK286104B6 (sk) * 1999-07-01 2008-03-05 Pharmacia & Upjohn Company Použitie (S,S) reboxetínu na prípravu lieku na liečenie alebo prevenciu chronickej bolesti
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
CN1660435A (zh) 2000-02-24 2005-08-31 法玛西雅厄普约翰美国公司 新的药物联合形式
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Also Published As

Publication number Publication date
US7723334B2 (en) 2010-05-25
TW200607512A (en) 2006-03-01
US7276503B2 (en) 2007-10-02
EP2087892A3 (de) 2009-09-30
CA2643231A1 (en) 2001-01-11
WO2001001973A8 (en) 2001-05-17
US6610690B2 (en) 2003-08-26
US6703389B2 (en) 2004-03-09
US7241762B2 (en) 2007-07-10
DE60023043D1 (de) 2006-02-16
IL147246A0 (en) 2002-08-14
KR20090087135A (ko) 2009-08-14
KR20020015363A (ko) 2002-02-27
SK286668B6 (sk) 2009-03-05
AU771258B2 (en) 2004-03-18
DE60026704D1 (de) 2006-05-11
EP2087892A2 (de) 2009-08-12
US6642235B2 (en) 2003-11-04
EA006652B1 (ru) 2006-02-24
ES2246485T3 (es) 2006-02-16
DE60026627D1 (de) 2006-05-04
DK1196172T3 (da) 2006-06-19
US20090247528A1 (en) 2009-10-01
US20080103147A1 (en) 2008-05-01
CN1289090C (zh) 2006-12-13
HK1049630A1 (en) 2003-05-23
KR100948757B1 (ko) 2010-03-23
WO2001001973A2 (en) 2001-01-11
US20040147614A1 (en) 2004-07-29
TW200607511A (en) 2006-03-01
JP2006143749A (ja) 2006-06-08
KR100935277B1 (ko) 2010-01-06
DK1459750T3 (da) 2005-08-15
ES2285645T3 (es) 2007-11-16
AU5633700A (en) 2001-01-22
ATE305306T1 (de) 2005-10-15
DE60022692D1 (de) 2005-10-20
ES2242175T3 (es) 2005-11-01
ES2247572T3 (es) 2006-03-01
TW200407146A (en) 2004-05-16
CN1205935C (zh) 2005-06-15
CN1660109A (zh) 2005-08-31
DE60020613D1 (de) 2005-07-07
DE60022692T2 (de) 2006-06-22
ES2246488T3 (es) 2006-02-16
IL187513A0 (en) 2008-06-05
ES2246487T3 (es) 2006-02-16
AR035158A1 (es) 2004-05-05
EA200200111A1 (ru) 2002-06-27
EA200400589A1 (ru) 2004-12-30
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01
EA005029B1 (ru) 2004-10-28
KR100717660B1 (ko) 2007-05-15
CL2008002868A1 (es) 2009-01-09
TWI298255B (en) 2008-07-01
DK1459749T3 (da) 2006-01-09
NZ515885A (en) 2004-08-27
TWI298254B (en) 2008-07-01
CN1660110A (zh) 2005-08-31
HUP0201623A2 (en) 2002-09-28
DE60026704T2 (de) 2006-10-19
US20060264436A1 (en) 2006-11-23
TW200607509A (en) 2006-03-01
DE60019473T2 (de) 2006-02-23
ATE304358T1 (de) 2005-09-15
JP2006321815A (ja) 2006-11-30
CN1379672A (zh) 2002-11-13
SK19382001A3 (sk) 2002-07-02
CA2375908C (en) 2006-05-30
ATE305307T1 (de) 2005-10-15
US20060128705A1 (en) 2006-06-15
ATE305788T1 (de) 2005-10-15
DE60035232D1 (de) 2007-07-26
NO20091158L (no) 2002-02-19
PL352252A1 (en) 2003-08-11
EA011094B1 (ru) 2008-12-30
TW200914027A (en) 2009-04-01
DE60019473D1 (de) 2005-05-19
HUP0201623A3 (en) 2004-12-28
ES2239311T3 (es) 2005-09-16
PT1459751E (pt) 2005-11-30
CZ20014625A3 (cs) 2002-08-14
TW200920378A (en) 2009-05-16
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
EA200801805A1 (ru) 2008-12-30
EA008381B1 (ru) 2007-04-27
SK286669B6 (sk) 2009-03-05
DE60022917D1 (de) 2006-02-09
DE60020613T2 (de) 2006-03-16
PE20010684A1 (es) 2001-06-24
ATE292971T1 (de) 2005-04-15
NO20091168L (no) 2002-02-19
PT1632234E (pt) 2007-07-09
NO20016406L (no) 2002-02-19
EA200700232A1 (ru) 2007-06-29
EP1196172A2 (de) 2002-04-17
WO2001001973A3 (en) 2002-01-17
US6465458B1 (en) 2002-10-15
TWI294779B (en) 2008-03-21
NZ533243A (en) 2005-12-23
PT1196172E (pt) 2006-05-31
HK1076723A1 (en) 2006-01-27
TW200607510A (en) 2006-03-01
NO20091159L (no) 2002-02-19
ES2258010T3 (es) 2006-08-16
CA2375908A1 (en) 2001-01-11
DE60026627T2 (de) 2007-02-01
ATE319453T1 (de) 2006-03-15
US20060142289A1 (en) 2006-06-29
ATE296634T1 (de) 2005-06-15
DE60022916D1 (de) 2006-02-09
DK1632234T3 (da) 2007-09-17
EP2090312A1 (de) 2009-08-19
MY137348A (en) 2009-01-30
US20030040464A1 (en) 2003-02-27
DE60023043T2 (de) 2006-06-14
ATE364386T1 (de) 2007-07-15
CO5190662A1 (es) 2002-08-29
PT1459750E (pt) 2005-08-31
US20020061910A1 (en) 2002-05-23
GEP20094798B (en) 2009-10-26
PL196996B1 (pl) 2008-02-29
CN1660108A (zh) 2005-08-31
CN1660111A (zh) 2005-08-31
KR20060099544A (ko) 2006-09-19
US20060135521A1 (en) 2006-06-22
AU2004202096A1 (en) 2004-06-10
US7317011B2 (en) 2008-01-08
US20080096890A1 (en) 2008-04-24
EP1196172B1 (de) 2006-03-15
US20080103146A1 (en) 2008-05-01
SK286104B6 (sk) 2008-03-05
US20020128173A1 (en) 2002-09-12
JP2003503450A (ja) 2003-01-28
DE60022916T2 (de) 2006-07-06
US20020107249A1 (en) 2002-08-08
MXPA02000562A (es) 2002-07-02
DE60022917T2 (de) 2006-06-29
EA200501496A1 (ru) 2006-06-30
KR20050053799A (ko) 2005-06-08
NO20016406D0 (no) 2001-12-28
SK286864B6 (sk) 2009-06-05
CZ299847B6 (cs) 2008-12-10
KR20090087134A (ko) 2009-08-14
SK286667B6 (sk) 2009-03-05
US7338953B2 (en) 2008-03-04
TWI245631B (en) 2005-12-21
EA200801806A1 (ru) 2008-12-30
KR100704319B1 (ko) 2007-04-09
ES2258251T3 (es) 2006-08-16
US6987107B2 (en) 2006-01-17
DE60035232T2 (de) 2008-02-14
CL2008002867A1 (es) 2009-01-09
CL2008002866A1 (es) 2009-01-09
AU2004202096B2 (en) 2005-10-20
IL187512A0 (en) 2008-06-05
BR0012136A (pt) 2002-06-11
US20060135520A1 (en) 2006-06-22
US20080103145A1 (en) 2008-05-01
TWI293250B (en) 2008-02-11

Similar Documents

Publication Publication Date Title
ATE320257T1 (de) (s,s)-reboxetine zur behandlung chronischer schmerzen
IL196301A0 (en) Medicament for the treatment of hapatitis c
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
FI20000863A (fi) Uusi hoitomenetelmä
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60032884D1 (de) Blutbehandlungssystem
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
DE60111520D1 (de) Hydroxyphenyl-piperazinyl-methyl-benzamid-derivate zur schmerzbehandlung
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE299371T1 (de) Antikonvulsiva zur behandlung von autismus
DE60005566D1 (de) Pyranoindole zur glaukombehandlung
IS2153B (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
ATE261965T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
ATE259809T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
GB0021652D0 (en) System for the extracorporeal treatment of blood
SE9903421D0 (sv) Behandlingsförfarande

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1196172

Country of ref document: EP

REN Ceased due to non-payment of the annual fee